Login to Your Account

Financings Roundup

Thursday, October 3, 2013

• Macrogenics Inc., of Rockville, Md., set terms for its initial public offering of 4 million shares at $14 to $16 per share. The offering is expected to raise about $60 million to support the company’s pipeline of monoclonal antibody-based therapeutics for cancer and autoimmune disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription